

**December 09**

**A. GENERAL INFORMATION**

**Name** Mithat Gönen, Ph.D.

**Office Address:**

Memorial Sloan-Kettering Cancer Center  
1275 York Avenue Box 44  
New York, NY 10021  
Telephone: (646) 735-8111  
Fax: (646) 735-0010  
E-mail: gonenm@mskcc.org

**B. EDUCATION BACKGROUND**

1986-1991 B.S. Electrical Engineering, Middle East Technical University  
1992-1993 M.S. Industrial Engineering, Stanford University  
1993-1996 M.S. Statistics, Texas Tech University  
1993-1996 Ph.D. Statistics, Texas Tech University

**C. PROFESSIONAL POSITIONS AND EMPLOYMENT**

**Academic Appointments:**

1996-1998 Biostatistician, Applied Logic Associates, Houston, TX  
1998.1999 Senior Statistical Scientist, Applied Logic Associates, Houston, TX  
1999.2005 Assistant Member, Memorial Sloan-Kettering Cancer Center  
2005-Present Associate Member, Memorial Hospital, Memorial Sloan-Kettering Cancer Center

**Hospital Appointments:**

1999-2005 Assistant Attending Biostatistician, Memorial Hospital for Cancer and Allied Diseases, New York, NY  
2005-present Associate Attending Biostatistician, Memorial Hospital for Cancer and Allied Diseases, New York, NY

**D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE****E. PROFESSIONAL MEMBERSHIPS**

<b>Member/Officer</b>	<b>Name of Organization</b>
Member (1996-present)	American Statistical Association
Member (1996-present)	International Biometric Society
Member (2009-present)	Society for Clinical Trials

**F. HONORS AND AWARDS**

1986-1990	Sabancı Foundation, Scholarship for Higher Education
1992-1996	Turkish Council for Higher Education, Scholarship for Graduate Study
1996	International Biometric Society (ENAR), Student Paper Award

**G. INSTITUTIONAL/HOSPITAL AFFILIATION**

Primary Hospital Affiliation	Memorial Hospital for Cancer and Allied Diseases, NY
------------------------------	--

**H. EMPLOYMENT STATUS**

Memorial Sloan-Kettering Cancer Center	Full-time
--	-----------

**I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT****1. Teaching:**

1990-1991	Teaching and Research Assistant, Middle East Technical University
1991-1992	Teaching Assistant, Texas Tech University
1994-1995	Teaching Assistant, Texas Tech University
1999-2001	Lecturer of Biostatistics, Cornell University

**2. Clinical Care**

N/A

**3. Administrative**

N.A

**4. Research:**

- Developing novel statistical methods to assess and validate prognostic models and cancer staging systems (2004-present)
- Development of risk prediction tools for patients undergoing resections of the hepatobiliary tract (2003-present)
- Improving colorectal cancer staging using nomograms (2005-present)
- Collaboration with Nuclear Medicine Physicians to design and analyze prospective and retrospective studies on the use of PET in various cancers (1999-present)
- Collaboration with gastrointestinal oncologists to design clinical trials on novel therapies to treat cancers of colon, rectum, stomach, esophagus and liver (1999-2005).
- Developing novel Bayesian methods for design and analysis of clinical data (1999-2005).

**J. RESEARCH SUPPORT****Past Support:**

- Early Therapeutics Development with Phase II Emphasis NCI 5 UO1 CM17105 (PI: Kelsen) 10% Effort (2001-2005) \$1,038,000
- Cancer Chemotherapy Program Project NCI 2 PO1 CA05826-38 (P.I. Bertino; Biostat. Core P.I. Begg) 10% Effort (2000-2005) \$1,038,000

**Current Support:**

- Targeted Blood Management for Surgical Resections, MSK Society, (PI: Gonen) 10% Effort (2005-2007) \$118,845.
- Individualized Risk Prediction of Complications to Liver Surgery, MSK Society, (PI: Gonen) 10% Effort (2006-2009). \$51,032.
- Clinical Trials of Flavopiridol with Chemotherapy NCI 2 R01 CA67819-5 A1 (PI: Schwartz), 20% Effort (2001-2009) \$187,216
- Molecular Mechanisms in GIST. NCI (PI: DeMatteo) 15% Effort. (2004-2009).
- Improving colorectal cancer staging with nomograms. AJCC (PI: Weiser). 10% Effort (2006-2007).
- Cancer Center Support Grant NCI 3 P30 CA08748-36 (P.I. Varmus; Biostat. Core P.I. Begg) 10% Effort (2001-2009) \$434,350 (Biostatistics Core)

- PET Imaging Fund (PI: Larson) NCI P50 CA 86438 (2003-2009) 20% effort

## **K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

### **Clinical Research**

- Member, Data Safety and Monitoring Board, “Antiviral and Antifibrotic Liver Therapy of HCV<sup>+</sup> Drinkers.” NIH-supported multi-center randomized trial. 2004-2008
- Member, Data Safety and Monitoring Board, “Home-Based Blood Pressure Interventions for African Americans.” NIH-supported multi-center randomized trial. 2005-2009
- Faculty, ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO, 2007-present. (Program Committee Member, 2009).
- Member, Editorial Board, *Gastrointestinal Cancer Research*, the official journal of the International Society of Gastrointestinal Oncology, 2007-present.
- Associate Editor, *Clinical Trials: Journal of the Society for Clinical Trials*, 2008-present.

### **National Institutes of Health**

- Member, NIH Review Panel “Genetic and Molecular Mechanisms of CAD Susceptibility and Progression” 2005
- Member, NIH Review Panel “Specialized Centers For Cell-Based Therapy (SCCT) For Heart, Lung, and Blood Diseases and Data and Coordinating Center (DCC)” 2005
- Member, Common Data Elements Committee For Phase II Clinical Trials, NCI, Cancer Therapy Evaluation Program. 2005-2006
- Member, NCI Study Section, Subcommittee J on Population and Patient-Based Training. 2006-2008.
- Reviewer, Deutsche Forschungsgemeinschaft (German Research Foundation) Life Sciences, 2007-2008.
- Reviewer, National Institute for Health Research UK, 2008.
- Member, NIH Special Emphasis Panel “NIDCR Small Research Grants for Data Analysis and Statistical Methodology (R03)”, 2009.

### **Service to the Statistical Community**

- Treasurer, Houston Area Chapter of the American Statistical Association, 1997-1999
- Executive Committee Member, New York City Chapter of the American Statistical Association, 2001-2003
- Vice President, New York City Chapter of the American Statistical Association, 2003-2008
- Member, Committee on International Relations in Statistics, American Statistical Association, 2006-2011 (President, 2010-2011).

**Intramural Service:**

- Member, Junior Faculty Council. 2004-2005.
- Member, Research Council. 2005-Present.
- Member, Data Integrity Investigation Committee, 2008-2009.
- Director and Faculty, Clinical Trials Workshop, 2008-Present.

**Invited Seminars Presented:**

1. *Bayesian analysis of variance components with Dirichlet priors.* Conference of Texas Statisticians, Houston, Texas, April 1997.
2. *Bayesian analysis of intraclass correlations in the mixed linear model.* Universite Catholique de Louvaine, Institute of Statistiques, Louvain-la-neuve, Belgium, March 1998.
3. *Bayesian methods in signal processing.* Rice University, Digital Signal Processing Research Group, Houston, Texas, October 1998.
4. *Bayes and frequentist methods for multiple inferences in drug experiments.* 1999 International Biometric Society (ENAR) Regional Conference, Atlanta, GA, March 1999.
5. *Bayesian multiple testing with correlated priors.* Southern Research Council on Statistics (SRCOS) Summer Conference, Mountain View, AR, June 1999.
6. *Bayesian multiple testing of multiple endpoints in clinical trials.* M.D. Anderson Cancer Center, Department of Biostatistics, Houston, TX, March 2000.
7. *A Bayesian look at the two-sample multivariate problem: connections with multiple testing.* New York State Psychiatric Institute, New York, NY, November 2002.
8. *Analysis of clustered binary pairs.* Texas Tech University, Department of Mathematics and Statistics, Lubbock, TX, April 2003.
9. *Testing marginal homogeneity with clustered binary data.* Penn State Medical School, Hershey, PA, September 2003. *Clinical trials and molecular biology.* New Jersey Cancer Institute, New Brunswick, NJ. March 2005.
10. *Receiver operating characteristic curves.* SAS Users Group International 31, San Francisco, CA. March 2006.
11. *Receiver operating characteristic curves.* Northeast SAS Users Group, Philadelphia, PA September 2006.

12. *Estimation Of Concordance Probability With Censored Data And Its Applications In Cancer Staging*. Columbia University Department of Biostatistics, October 2006.
13. *Estimation of Concordance with Censored Data*. Johns Hopkins University, Bloomberg School of Public Health, November 2007.
14. *Concordance Probability in Presence of Censoring with Applications to Cancer Staging and Biomarkers*. Stanford University, Department of Biostatistics, February 2008.
15. *ROC Curves for the Uninitiated*. (Tutorial) International Biometric Society (ENAR) Spring Conference, Washington DC, March 2008.
16. *Evaluation of Prognostic Models using Area Between Curves (ABC)*. Joint Statistical Meetings, Denver, CO, August 2008.
17. *Statistical Aspects of Gene Signatures and Molecular Targets*. International Society of Gastrointestinal Oncology, Arlington, VA. September 2008.
18. *An extension of the c-index for Cox models*. Cleveland Clinic Foundation, Department of Quantitative Sciences. October 2008.
19. *Evaluation and Validation of Cox Models Using Concordance Probability*. University of Wisconsin, Department of Biostatistics and Bioinformatics, February 2009.
20. *ROC Curves without Tears*. (Short Course) International Biometric Society (EMR) Conference, Istanbul, Turkey, May 2009.
21. *Statistical Issues in Solid Tumor Response Assessment*, Roundtable Discussion Leader, FDA/Industry Statistics Workshop, Washington DC, September 2009.
22. *Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer*. Bayesian Biostatistics 2010, Houston, TX, January 2010.
23. *Simultaneous Use of Historical and Randomized Controls in Phase II Trials*. Society of Clinical Trials Meeting, Baltimore, MD, May 2010.

**L. BIBLIOGRAPHY****Book**

1. **Gönen M.** Receiver Operating Characteristic Curves Using SAS®. SAS Press, Cary, NC. 2007.

**Book Chapters**

1. Kattan MW, **Gönen M**, Scardino PT. The development and execution of medical prediction models. In *Outcome Prediction in Cancer*. Edited by Taktak AFG, Fisher AC. Elsevier. 2007.
2. **Gönen M.** Bayesian Analysis. In Kattan MW (editor) *Encyclopedia of Medical Decision Making*. Sage, 2009.
3. **Gönen M.** Bayesian t-test and Beyond. In Bang, H, Zhou, XK, Van Epps, H, Mazumdar, M. (editors) *Statistical Methods in Molecular Biology*. Humana Press, Springer. To be published in 2010.

**Peer-Reviewed Articles**

1. Westfall P, **Gönen M**: Asymptotic properties of ANOVA Bayes Factors. *Communications in Statistics: Theory and Methods* 1996;25:3103-3123.
2. **Gönen M**, Puri M, Ruymgaart F, Van Zuijlen M: The limiting density of unit-root test statistics: unknown mean, dependent errors. *Journal of Time Series Analysis*. 2000;21:249-260.
3. **Gönen M**: A Bayesian analysis of intraclass correlations in the mixed linear model. *Communications in Statistics: Theory and Methods* 2000;29:1451-1464.
4. Sharma S, **Gönen M**: Fluoropyrimidine chemotherapy improves 1-year mortality in people with stage IV or unresectable colorectal cancer compared with supportive care. *J of Evidence-Based Oncology* 2000;1:116.
5. Ramos CD, Erdi YE, **Gönen M**, Riedel ER, Yeung WD, Macapinlac HA, Chisin R, Larson SM: FDG-PET standardized uptake values in normal anatomical structures using IRSAC and FBP. *J Nucl Med* 2001;28:155-164.
6. Abraham M, **Gönen M**, Kraus D: Complications of Type I thyroplasty and arytenoid adduction. *Laryngoscope* 2001;111:1322-1329.
7. Yeung HWD, Cody HS, Turlakow A, Riedel ER, Fey J, **Gönen M**, Nunez R, Yeh SD, Larson SM: LSG and SNL at surgery in breast cancer patients: Comparison between one-day and two-day protocols. *J Nucl Med* 2001;42:420-423.
8. Kemeny N, **Gönen M**, Sullivan D, Schwartz L, Benedetto F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J: A Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *J Clin Oncol* 2001;19:2687-2695.

9. Jarnagin WR, Fong Y, DeMatteo RP, **Gönen M**, Burke EC, Bodniewicz J, Youseff M, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001;234:507-517.
10. Motwani M, Jung C, Sirotiak FM, She Y, Shah MA, **Gönen M**, Schwartz G: Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. *Clin Cancer Res* 2001;7:4209-4219.
11. **Gönen M**, Panageas KS, Larson SM: Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. *Radiology* 2001;221:763-767.
12. Turlakow A, Larson S, Coakley F, Akhurst T, **Gönen M**, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P: Local detection of prostate-cancer by positron-emission-tomography with 2-fluorodeoxy-glucose-comparison of filtered back-projection and iterative reconstruction with segmented attenuation correction. *Quarterly J Nucl Med* 2001;45:235-244.
13. Nuñez R, Macapinlac HA, Yeung HWD, Akhurst T, Sai SD, Osman I, **Gönen M**, Riedel E, Scher HI, Larson SM: Combined F-18-FDG and C-11 methionine PET scans in patients with newly progressive metastatic prostate cancer. *J Nucl Med* 2002;43:46-55.
14. Akhurst T, Downey RJ, Ginsberg MS, **Gönen M**, Bains M, Korst R, Ginsberg RJ, Rusch V, Larson SM: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. *Ann of Thorac Surg* 2002;73:259-264.
15. Petrowski H, **Gönen M**, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y: 2<sup>nd</sup> liver resections are safe and effective treatment for recurrent colorectal cancer hepatic metastases from colorectal cancer – A bi-institutional analysis. *Ann Surg* 2002;235:863-870.
16. Ross PL, Gerigk C, **Gönen M**, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW: Comparisons of nomograms and urologists' predictions in prostate cancer. *Sem Urolo Oncol* 2002;20:82-88.
17. Panageas KS, Smith A, **Gönen M**, Chapman PB: An optimal 2-stage phase II design utilizing complete and partial response information separately. *Control Clin Trials* 2002; 23:367-379.
18. Kemeny N, Tong W, **Gönen M**, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. *Ann Oncol.* 2002;13:1490-1496.
19. Etchebehere EC, Macapinlac HA, **Gönen M**, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM: Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18F-FDG PET. *Q J Nucl Med.* 2002.46:122-130.
20. Holen KD, Klimstra DK, Hummer A, **Gönen M**, Conlon K, Brennan M, Saltz LB. Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. *J Clin Oncol.* 2002;20:4673-4678.

21. Wong RJ, Lin DT, Schoder H, Patel SG, **Gönen M**, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol*. 2002;20:4199-4208.
22. Jarnagin WR, **Gönen M**, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection – analysis of 1803 consecutive cases over the past decade. *Ann Surg*. 2002;236:397-407.
23. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, **Gönen M**, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. *Surgery* 2002;132:353-359.
24. Allen PJ, Stojadinovic A, Ben-Porat L, **Gönen M**, Kooby D, Blumgart L, Paty P, Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. *Ann Surg Oncol*. 2002;9:875-80.
25. Pandit-Taskar N, **Gönen M**, Krug L, Larson SM. Prognostic value of 18FDG-PET imaging in small cell lung cancer. *European J Nucl Med & Molecular Imaging* 2003;30:78-84.
26. **Gönen M**, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. *J Clin Oncol* 2003;21:406-412.
27. Downey RJ, Akhurst T, Ilson D, Ginsberg, R, Bains MS, **Gönen M**, Koong H, Gollub M, Larson SM, Minsky B, Zakowski M, Turnbull A, Rusch V. Whole body 18FDG-PET measurement of the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003;21:428-432.
28. D'Angelica M, Fong Y, Weber S, **Gönen M**, DeMatteo RP, Conlon K, Blumgart LH, Jarnagin WR. A prospective analysis of staging laparoscopy in 401 patients with primary and secondary hepatobiliary malignancy. *Ann Surg Oncol*. 2003;10:183-189.
29. **Gönen M**, Westfall PH, Johnson WO. Bayesian multiple testing for two-sample multivariate endpoints. *Biometrics*. 2003;59:76-82.
30. Shoup M, **Gönen M**, D'Angelica M, Jarnagin W, DeMatteo R, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg* 2003;7:325-330.
31. Kooby DA, Stockman J, Ben-Porat L, **Gönen M**, Jarnagin WR, DeMatteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg*. 2003;237:860-870
32. **Gönen M**. Planning for subgroup analysis: A case study in metastatic colorectal cancer. *Control Clin Trials*. 2003;24:355-363.

33. Flores RM, Akhurst T, **Gönen M**, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. *J Thorac Cardiovasc Surg.* 2003;126:11-16.
34. Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, **Gönen M**, Wilson K, Minsky BD. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. *J Clin Oncol.* 2003;1;21:2926-32
35. Kemeny N, Jarnagin W, **Gönen M**, Stockman J, Blumgart L, Sperber D, Hummer A, Fong Y. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. *J Clin Oncol.* 2003;21:3303-3309
36. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, **Gönen M**, Kattan MW, Catalona WJ. A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session. *J Urol* 2003;170:1184-1188.
37. Yeung HWD, Grewal RK, **Gönen M**, Schoder H, Larson SM. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET. *J Nucl Med* 2003;44:1789-1796
38. Hann LE, Kim CM, **Gönen M**, Barakat R, Choi PH, Bach AM. Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifen-Treated Women. *J Ultrasound Med* 2003;22:1173-1179.
39. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, **Gönen M**, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *J Urol.* 2003;170:2292-2295.
40. Weitz J, D'Angelica M, **Gönen M**, Klimstra D, Coit DG, Brennan MF, Karpeh MS. Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. *J Clin Oncol.* 2003;21:4597-4603
41. Jung C, Motwani M, Kortmanky J, Sirotnak FM, She Y, **Gönen M**, Haimowitz-Friedman A, Schwartz GK. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates {gamma}-Irradiation Induced Apoptosis in Colon and Gastric Cancer Cells. *Clin. Cancer Res.*2003;9:6052-6061.
42. Kooby DA, Fong Y, Suriawinata A, **Gönen M**, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR. Impact of steatosis on perioperative outcome following hepatic resection. *J Gastrointest Surg.* 2003;7:1034-1044.
43. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, **Gönen M**, Kelsen DP. Phase I Trial of Combined-Modality Therapy for Localized Esophageal Cancer: Escalating Doses of Continuous-Infusion Paclitaxel With Cisplatin and Concurrent Radiation Therapy. *J Clin Oncol* 2004;22:45-52.

44. Schoder H, Yeung HWD, **Gönen M**, Kraus D, Larson SM. Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. *Radiology* 2004;231:65-72
45. Schoder H, Erdi YE, Chao K, **Gönen M**, Larson SM, Yeung HWD. Clinical Implications of Different Image Reconstruction Parameters for Interpretation of Whole-Body PET Studies in Cancer Patients. *J Nucl Med.* 2004;45:559-566.
46. Weitz J, D'angelica M, Jarnagin W, **Gönen M**, Fong Y, Blumgart L, DeMatteo R. Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. *Surgery.* 2004;135:273-281.
47. Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, **Gönen M**, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. *Clin Cancer Res.* 2004 1;10:3225-3232.
48. Brenner B, Shah MA, **Gönen M**, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. *BR.J Cancer* 2004;4;90:1720-1726.
49. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, **Gönen M**, Segal NH, Maki RG, Succi ND, DeMatteo RP, Besmer P. Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. *Clin Cancer Res* 2004;2010:3282-3290.
50. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, **Gönen M**, Kattan MW, Onyebuchi CN, Scardino PT. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. *Cancer* 2004;100:2655-2663.
51. **Gönen M**. Sample size and power for McNemar's test with clustered data. *Statist. Med.* 2004;23:2283-2294.
52. Carlo WF, Hummer AJ, Schwartz L, Sullivan D, **Gönen M**, Jarnagin W, Fong Y, Kemeny N. Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. *J Surg Oncol.* 2004;87:85-90.
53. Downey RJ, Akhurst T, **Gönen M**, Vincent A, Bains MS, Larson SM, Rusch V. Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection. *J Clin Oncol* 2004; 22; 3255–3260.
54. Pandit-Taskar N, Schoder H, **Gönen M**, Larson SM, Yeung HWD. Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. *AJR AM J Roentgenol* 2004;183:1143-1147.
55. D'Angelica M, **Gönen M**, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma. *Ann Surg.* 2004;240:808-816.
56. Yanke BV, **Gönen M**, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. *J Urol.* 2005;173:421-424.

57. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, **Gönen M**, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. *J Clin Oncol*. 2005;23:1875-1884.
58. Kemeny N, **Gönen M**. Hepatic arterial infusion after liver resection.(Letter) *N Engl J Med*. 2005;352:734-735.
59. Spanknebel K, Coit DG, Bieligk SC, **Gönen M**, Rosai J, Klimstra DS. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis. *Am J Surg Pathol*. 2005;29:305-317.
60. Hawkins WG, Dematteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, **Gönen M**, Blumgart LH. Caudate hepatectomy for cancer: A single institution experience with 150 patients. *J Am Coll Surg*. 2005;200:345-52.
61. **Gönen M**. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. *Contemp Clin Trials* 2005;26:131-140.
62. Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, **Gönen M**, Schwartz GK. *Drg1* Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. *Clin Cancer Res* 2005 11:3296-3302.
63. Schoder H, Noy A, **Gönen M**, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. *J Clin Oncol*. 2005;23:4577-4580.
64. Vural B, Chen LC, Saip P, Chen YT, Ustuner Z, **Gönen M**, Simpson AJ, Old LJ, Ozbek U, Gure AO. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. *Cancer*. 2005;103:2575-2583.
65. Yeung HW, Schoder H, Smith A, **Gönen M**, Larson SM. Clinical Value of Combined PET/CT Imaging in the Interpretation of FDG PET Studies in Cancer Patients. *Mol Imaging Biol*. 2005;7:229-235
66. Shah MA, Kortmansky J, Motwani M, Drobnjak M, **Gönen M**, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. *Clin Cancer Res* 2005;11:3836-3845.
67. Specht, Kattan MW, **Gönen M**, Fey J, VanZee KJ. Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. *Ann Surg Oncol*. 2005;12:654-659.

68. Schoder H, Hermann K, **Gönen M**, Hricak H, Eberhard S, Scardino P, Scher H, Larson SM. 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. *Clin Cancer Res.* 2005;11:4761-4769.
69. **Gönen M**. Planning a dose-response study when doses are subject-specific. *Statist Med.* 2005; 24:2613-2623.
70. Maluccio M, Covey AM, Gandhi R, **Gönen M**, Getrajdman GI, Brody LA, Fong Y, Jarnagin W, D'Angelica M, Blumgart L, Dematteo R, Brown KT. Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. *J Vasc Interv Radiol.* 2005;16:955-961.
71. Kemeny N, Jarnagin W, Paty P, **Gönen M**, Schwartz L, Morse M, Leonard G, D'Angelica M, Dematteo R, Blumgart L, Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *J Clin Oncol.* 2005;23:4888-4896.
72. Kemeny N, Eid A, Stockman J, **Gönen M**, Schwartz L, Tetzlaff E, Paty P. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. *J Surg Oncol.* 2005;18:91:97-101.
73. **Gönen M**, Johnson WO, Lu T, Westfall PH. The Bayesian two-sample t-test. *The American Statistician*, 2005; 59: 252-257.
74. Kraus DH, **Gönen M**, Mener D, Brown AE, Bilsky MH, Shah JP. A Standardized Regimen of Antibiotics Prevents Infectious Complications in Skull Base Surgery. *Laryngoscope.* 2005;115:1347-1357.
75. Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, **Gönen M**, Ebright MI, Culliford A, Gusani NJ, Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. *Cancer Gene Ther.* 2006; 13:326-334.
76. Bennett J, **Gönen M**, D'Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? *J Am Coll Surg.* 2005;201:503-510.
77. Fong Y, **Gönen M**, Rubin M, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. *Ann Surg.* 2005;242:540-547.
78. Liao KH, Ruo L, Shia J, Padela A, **Gönen M**, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. *Cancer*, 2006;104:1945-1955.
79. Howard MA, Cordeiro P, Disa J, Samson W, **Gönen M**, Schoelle H, Mehrara B. Free tissue transfer in the elderly: incidence of perioperative complications following microsurgical reconstruction of 197 septuagenarians and octogenarians. *Plast Reconstr Surg.* 2005;116:1659-68.

80. **Gönen M**, Heller G. Concordance probability and discriminatory power in proportional hazards regression. *Biometrika*,2005;92:965-970.
81. Gure AO, Chua R, Williamson B, **Gönen M**, Ferrera CA, Gnjatic S, Ritter G, Simpson AJG, Chen YT, Old LJ, Altorki NK. Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2005;11: 8055-8062.
82. Robbins RJ, Wan Q, Grewal RK, Reibke R, **Gönen M**, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time Prognosis for Metastatic Thyroid Carcinoma Based on FDG-PET Scanning. *J Clin Endocrinol Metab.* 2006; 91:498-505.
83. Mullerad M, Eisenberg DP, Akhurst TJ, Adusumilli PS, Riedl CC, Bhargava A, **Gönen M**, Finn R, Scardino PT, Fong Y. Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus. *Mol Imaging Biol.* 2006; 8:30-35.
84. Toner LE, Vrhovac R, Smith EA, Jeffrey G, Heaney M, **Gönen M**, Teruya-Feldstein J, Sirotinak F, O'Connor OA. The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma. *Clin Cancer Res* 2006;12 924-932
85. D'Angelica M, Maddineni S, Fong Y, Martin RC, Cohen MS, Ben-Porat L, **Gönen M**, DeMatteo RP, Blumgart LH, Jarnagin WR. Optimal Abdominal Incision for Partial Hepatectomy: Increased Late Complications with Mercedes-type Incisions Compared to Extended Right Subcostal Incisions. *World J Surg.* 2006; 30:410-418.
86. Yoon S, Kim SH, **Gönen M**, Heffernan N, Detwiler KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, DeMatteo RP. Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. *Ann Surg Oncol.* 2006;13:353-362.
87. Brady MS, Akhurst T, Spanknebel K, Hilton S, **Gönen M**, Patel A, Larson S. Utility of Preoperative [(18)F]Fluorodeoxyglucose-Positron Emission Tomography Scanning in High-Risk Melanoma Patients. *Ann Surg Oncol.* 2006;13:525-532.
88. Rizk N, Downey RJ, Akhurst T, **Gönen M**, Bains M, Larson SM, Rusch V. Preoperative FDG-PET SUV predicts survival after esophageal adenocarcinoma resection. *Ann Thorac Surg.* 2006;81:1076-1081.
89. Jarnagin WR, Klimstra DS, Hezel M, **Gönen M**, Fong Y, Roggin K, Cyrnes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B. Differential cell cycle regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables and clinical outcome. *J Clin Oncol.* 2005;23:1875-1884.
90. Port E, Yeung H, **Gönen M**, Liberman L, Caravelli J, Borgen P, Larson S. (18)F-2-Fluoro-2-Deoxy-D: -Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma. *Ann Surg Oncol.* 2006;13:677-684.

91. Santiago JF, **Gönen M**, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of (18)F-FDG PET scans on clinical management of 133 breast cancer patients. *Q J Nucl Med Mol Imaging*. 2006;50:61-67.
92. Schoder H, Carlson DL, Kraus DH, Stambuk HE, **Gönen M**, Erdi YE, Yeung HWD, Huvos AG, Shah JP, Larson SM, Wong RJ. 18F-FDG PET/CT for Detecting Nodal Metastases in Patients with Oral Cancer Staged N0 by Clinical Examination and CT/MRI. *J Nucl Med* 2006;47:755-762
93. Stiles BM, Adusumilli PS, Stanziale SF, Eisenberg DP, Bhargava A, Kim TH, Chan MK, Huq R, **Gönen M**, Fong Y. Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. *Int J Oncol*. 2006;28:1429-1439.
94. Fong Y, Wagman L, **Gönen M**, Crawford J, Reed W, Swanson R, Pan C, Ritchey J, Stewart A, Choti M. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. *Annals of Surgery*; 2006;243:767-771.
95. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. *Ann Oncol*. 2006 Jun 20; *Ann Oncol*, 2006;17:1404-1411
96. Budak-Alpdogan T, Przybylowski M, **Gönen M**, Sadelain M, Bertino J, Riviere I. Functional Assessment of the Engraftment Potential of Gammaretrovirus-Modified CD34(+) Cells, Using a Short Serum-Free Transduction Protocol. *Hum Gene Ther*. 2006; 17:780-94.
97. Grobmyer SR, Wang L, **Gönen M**, Fong Y, Klimstra D, D'angelica M, Dematteo RP, Schwartz L, Blumgart LH, Jarnagin WR. Perihepatic Lymph Node Assessment in Patients Undergoing Partial Hepatectomy for Malignancy. *Ann Surg*. 2006;244:260-264.
98. Gerecitano J, Goy A, Wright J, Macgregor-Cortelli B, Neylon E, **Gönen M**, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O'Connor OA. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? *Br J Haematol*. 2006;134:391-398.
99. Pryma DA, Schoder H, **Gönen M**, Robbins RJ, Larson SM, Yeung HW. Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients. *J Nucl Med*. 2006;47:1260-1266.
100. Allen PJ, D'Angelica M, **Gönen M**, Jaques DP, Coit DG, Jarnagin WR, DeMatteo R, Fong Y, Blumgart L, Brennan MF. A Selective Approach to the Resection of Cystic Lesions of the Pancreas: Results From 539 Consecutive Patients. *Ann Surg*. 2006 Oct;244(4):572-582.
101. Flores R, Akhurst T, **Gönen M**, Zakowski M, Dycoco J, Larson SM, Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg*. 2006 Oct;132(4):763-8.

102. Gold JS, van der Zwan SM, **Gönen M**, Maki RG, Singer S, Brennan MF, Antonescu CR, Dematteo RP. Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. *Ann Surg Oncol*. 2006 Nov 2; [Epub ahead of print]
103. Are C, **Gönen M**, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Differential diagnosis of proximal biliary obstruction. *Surgery*. 2006 Nov;140(5):756-63. Epub 2006 Jul 28.
104. Barbour AP, Rizk NP, **Gönen M**, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome. *Ann Surg Oncol*. 2006 Nov 8; [Epub ahead of print]
105. D'Angelica M, Kornprat P, **Gönen M**, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny NK, Blumgart LH, Saltz LB. Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. *Surg Oncol*. 2006 Nov 11; [Epub ahead of print]
106. Kornprat P, Jarnagin WR, **Gönen M**, Dematteo RP, Fong Y, Blumgart LH, D'Angelica M. Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy. *Ann Surg Oncol*. 2006 Dec 31; [Epub ahead of print]
107. Schoder H, **Gönen M**. Screening for Cancer with PET and PET/CT: Potential and Limitations. *J Nucl Med*. 2007;48 Suppl:4S-18S.
108. Yeh JJ, **Gönen M**, Tomlinson JS, Idrees K, Brennan MF, Fong Y. Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas. *Br J Surg*. 2007.
109. Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, **Gönen M**, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 ((124)I-cG250) and PET in patients with renal masses: a phase I trial. *Lancet Oncol*. 2007 Apr;8(4):304-10.
110. Ong SC, Schoder H, Patel SG, Tabangay-Lim IM, Doddamane I, **Gönen M**, Shaha AR, Tuttle RM, Shah JP, Larson SM. Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. *J Nucl Med*. 2007 Apr;48(4):501-507.
111. DeMatteo RP, Maki RG, Singer S, **Gönen M**, Brennan MF, Antonescu CR. Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. *Ann Surg*. 2007 Mar;245(3):347-352.
112. Parks R, Gönen M, Kemeny N, Jarnagin W, D'Angelica M, Dematteo R, Garden OJ, Blumgart LH, Fong Y. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. *J Am Coll Surg*. 2007 May;204(5):753-61. Epub 2007 Feb 23.

113. Downey RJ, Akhurst T, **Gönen M**, Park B, Rusch V. Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2007 Jun;133(6):1419-27. Epub 2007 May 2.
114. Barbour AP, Rizk NP, **Gönen M**, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF. Adenocarcinoma of the Gastroesophageal Junction: Influence of Esophageal Resection Margin and Operative Approach on Outcome. *Ann Surg.* 2007 Jul;246(1):1-8.
115. Gold JS, Tang LH, **Gönen M**, Coit DG, Brennan MF, Allen PJ. Utility of a Prognostic Nomogram Designed for Gastric Cancer in Predicting Outcome of Patients with R0 Resected Duodenal Adenocarcinoma. *Ann Surg Oncol.* 2007 Aug 7; [Epub ahead of print]
116. Are C, **Gönen M**, Zazzali K, Dematteo RP, Jarnagin WR, Fong Y, Blumgart LH, D'Angelica M. The impact of margins on outcome after hepatic resection for colorectal metastasis. *Ann Surg.* 2007 Aug;246(2):295-300.
117. Park JO, **Gönen M**, D'Angelica MI, Dematteo RP, Fong Y, Wuest D, Blumgart LH, Jarnagin WR. Autologous Versus Allogeneic Transfusions: No Difference in Perioperative Outcome After Partial Hepatectomy : Autologous Transfusion on Hepatectomy Outcome. *J Gastrointest Surg.* 2007 Jul 31; [Epub ahead of print]
118. Strong VE, D'Angelica M, Tang L, Prete F, **Gönen M**, Coit D, Touijer KA, Fong Y, Brennan MF. Laparoscopic Adrenalectomy for Isolated Adrenal Metastasis. *Ann Surg Oncol.* 2007 Jul 31; [Epub ahead of print]
119. Miller G, Biernacki P, Kemeny NE, **Gönen M**, Downey R, Jarnagin WR, D'Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. *J Am Coll Surg.* 2007 Aug;205(2):231-8. Epub 2007 Jun 27.
120. House MG, **Gönen M**, Jarnagin WR, D'Angelica M, Dematteo RP, Fong Y, Brennan MF, Allen PJ. Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer. *J Gastrointest Surg.* 2007 Sep 4; [Epub ahead of print]
121. Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, **Gönen M**, Quinones M, Morse M, Chen HX. Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study. *J Clin Oncol.* 2007 Sep 17; [Epub ahead of print]
122. Dalal KM, Woo Y, Galanis C, **Gönen M**, Tang L, Allen P, Dematteo R, Fong Y, Coit DG. Detection of Micrometastases in Peritoneal Washings of Pancreatic Cancer Patients by the Reverse Transcriptase Polymerase Chain Reaction. *J Gastrointest Surg.* 2007 Sep 19; [Epub ahead of print]
123. Sofocleous CT, Nascimento RG, **Gönen M**, Theodoulou M, Covey AM, Brody LA, Solomon SM, Thornton R, Fong Y, Getrajdman GI, Brown KT. Radiofrequency ablation in the management of liver metastases from breast cancer. *Am J Roentgenol.* 2007 Oct;189(4):883-9.

124. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, **Gönen M**, Kelsen DP, Brennan MF, Coit DG. Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer? *Ann Surg Oncol*. 2007 Oct 2; [Epub ahead of print]
125. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, **Gönen M**, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol*. 2007 Oct 10;25(29):4575-80.
126. Ferrone CR, Brennan MF, **Gönen M**, Coit DG, Fong Y, Chung S, Tang L, Klimstra D, Allen PJ. Pancreatic Adenocarcinoma: The Actual 5-Year Survivors. *J Gastrointest Surg*. 2007 Nov 20; [Epub ahead of print]
127. Lassmann S, Tang L, Capanu M, Brabletz T, Schöpflin A, Zur Hausen A, **Gönen M**, Kemeny N, Shia J, Klimstra D, Werner M. Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. *Gastroenterology*. 2007 Dec;133(6):1831-9. Epub 2007 Sep 5.
128. Ferrone CR, Tang LH, Tomlinson J, **Gönen M**, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? *J Clin Oncol*. 2007 Dec 0;25(35):5609-15.
129. House MG, Fong Y, Arnaoutakis DJ, Sharma R, Winston CB, Protic M, **Gönen M**, Olson SH, Kurtz RC, Brennan MF, Allen PJ. Preoperative Predictors for Complications after Pancreaticoduodenectomy: Impact of BMI and Body Fat Distribution. *J Gastrointest Surg*. 2008 Feb;12(2):270-8
130. DeMatteo RP, Gold JS, Saran L, **Gönen M**, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). *Cancer*. 2008 Feb 1;112(3):608-15
131. Gold JS, Are C, Kornprat P, Jarnagin WR, **Gönen M**, Fong Y, DeMatteo RP, Blumgart LH, D'Angelica M. Increased Use of Parenchymal-Sparing Surgery for Bilateral Liver Metastases From Colorectal Cancer Is Associated With Improved Mortality Without Change in Oncologic Outcome: Trends in Treatment Over Time in 440 Patients. *Ann Surg*. 2008 Jan;247(1):109-117.
132. Ghosh P, **Gönen M**. Bayesian modeling of multivariate average bioequivalence. *Stat Med*. 2007 Dec 19; [Epub ahead of print]
133. Weiser MR, Landmann RG, Kattan MW, **Gönen M**, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD. Individualized prediction of colon cancer recurrence using a nomogram. *J Clin Oncol*. 2008 Jan 20;26(3):380-5.
134. Sawai A, Chandarlapaty S, Greulich H, **Gönen M**, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. *Cancer Res*. 2008 Jan 15;68(2):589-96.

135. Kattan MW, **Gönen M**, Jarnagin WR, Dematteo R, D'Angelica M, Weiser M, Blumgart LH, Fong Y. A Nomogram for Predicting Disease-specific Survival After Hepatic Resection for Metastatic Colorectal Cancer. *Ann Surg.* 2008 Feb;247(2):282-287.
136. Vickers AJ, Bianco FJ, **Gönen M**, Cronin AM, Eastham JA, Schrag D, Klein EA, Reuther AM, Kattan MW, Pontes JE, Scardino PT. Effects of Pathologic Stage on the Learning Curve for Radical Prostatectomy: Evidence That Recurrence in Organ-Confined Cancer Is Largely Related to Inadequate Surgical Technique. *Eur Urol.* 2008 Jan 14; [Epub ahead of print]
137. Cho CS, **Gönen M**, Shia J, Kattan MW, Klimstra DS, Jarnagin WR, D'Angelica MI, Blumgart LH, DeMatteo RP. A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma. *J Am Coll Surg.* 2008 Feb;206(2):281-91. Epub 2007 Oct 29.
138. Paoluzzi L, **Gönen M**, Gardner JR, Mastrella J, Yang D, Holmlund J, Sorensen M, Leopold L, Manova K, Marcucci G, Heaney ML, O' Connor OA. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. *Blood.* 2008 Feb 21; [Epub ahead of print].
139. White R, Winston C, **Gönen M**, D'Angelica M, Jarnagin W, Fong Y, Conlon K, Brennan M, Allen P. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. *J Am Coll Surg.* 2008 Mar;206(3):445-50. Epub 2007 Nov 26.
140. Quah HM, Chou JF, **Gönen M**, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR. Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy. *Dis Colon Rectum.* 2008 Mar 6; [Epub ahead of print]
141. Shia J, Klimstra DS, Nitzkorski JR, Low PS, **Gönen M**, Landmann R, Weiser MR, Franklin WA, Prendergast FG, Murphy L, Tang LH, Temple L, Guillem JG, Wong WD, Paty PB. Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. *Hum Pathol.* 2008 Apr;39(4):498-505.
142. D'Angelica M, **Gönen M**. Impact of Margin Width on Outcome After Resection of Colorectal Liver Metastases. *Ann Surg.* 2008 May;247(5):905-906.
143. Quah HM, Chou JF, **Gönen M**, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. *Cancer.* 2008 Apr 28. [Epub ahead of print]
144. **Gönen M** Area between curves: what you see is not what you get. *J Clin Oncol.* 2008 May 1;26(13):2236
145. Kattan MW, **Gönen M**. The prediction philosophy in statistics. *Urol Oncol.* 2008 May-Jun;26(3):316-9. Epub 2007 Nov 7.
146. Can AS, Bersot TP, **Gönen M**. Anthropometric indices and their relationship with cardiometabolic risk factors in a sample of Turkish adults. *Public Health Nutr.* 2008 May 19:1-9. [Epub ahead of print]

147. Ito H, Are C., **Gönen M**, D'Angelica M, Dematteo RP, Kemeny NE, Fong Y, Blumgart LH, Jarnagin WR. Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. *Ann Surg.* 2008 Jun;247(6):994-1002.
148. Endo I, **Gönen M**, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. *Ann Surg.* 2008 Jul;248(1):84-96.
149. Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, **Gönen M**, Scher HI, Larson SM, Divgi CR. Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using <sup>111</sup>In-J591: Lesion Detectability and Dosimetric Projections for <sup>90</sup>Y Radioimmunotherapy. *J Nucl Med.* 2008 Jun 13. [Epub ahead of print]
150. Endo I, House MG, Klimstra DS, **Gönen M**, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Clinical Significance of Intraoperative Bile Duct Margin Assessment for Hilar Cholangiocarcinoma. *Ann Surg Oncol.* 2008 Jun 10. [Epub ahead of print]
151. Paoluzzi L, **Gönen M**, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. *Blood.* 2008 Jun 30. [Epub ahead of print]
152. Elkin EB, Ishill N, Riley GF, Bach PB, **Gönen M**, Begg CB, Schrag D. Disenrollment from medicare managed care among beneficiaries with and without a cancer diagnosis. *J Natl Cancer Inst.* 2008 Jul 16;100(14):1013-21. Epub 2008 Jul 8.
153. Barbour AP, Jones M, **Gönen M**, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. *Ann Surg Oncol.* 2008 Jul 29. [Epub ahead of print]
154. Jarnagin WR, **Gönen M**, Maithel SK, Fong Y, D'Angelica MI, Dematteo RP, Grant F, Wuest D, Kundu K, Blumgart LH, Fischer M. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. *Ann Surg.* 2008 Sep;248(3):360-9.
155. Maithel SK, Maloney S, Winston C, **Gönen M**, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ. Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma. *Ann Surg Oncol.* 2008 Sep 10. [Epub ahead of print].
156. Sofocleous CT, Nascimento RG, Petrovic LM, Klimstra DS, **Gönen M**, Brown KT, Brody LA, Covey AM, Thornton RH, Fong Y, Solomon SB, Schwartz LH, DeMatteo RP, Getrajdman GI. Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. *Radiology.* 2008 Oct;249(1):364-74.

157. Greco C, Nehmeh SA, Schöder H, **Gönen M**, Raphael B, Stambuk HE, Humm JL, Larson SM, Lee NY. Evaluation of different methods of 18F-FDG-PET target volume delineation in the radiotherapy of head and neck cancer. *Am J Clin Oncol*. 2008 Oct;31(5):439-45.
158. Tse AN, Klimstra DS, **Gönen M**, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, Chung K, Maki R, Lefkowitz R, Brown K, Manova-Todorova K, Wu N, Egorin MJ, Kelsen D, Schwartz GK. A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors. *Clin Cancer Res*. 2008 Oct 15;14(20):6704-6711.
159. Ariyan C, Brady MS, **Gönen M**, Busam K, Coit D. Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma. *Ann Surg Oncol*. 2008 Nov 1. [Epub ahead of print]
160. Allen PJ, Reiner AS, **Gönen M**, Klimstra DK, Blumgart LH, Brennan MF, D'Angelica M, Dematteo R, Fong Y, Jarnagin WR. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. *HPB (Oxford)*. 2008;10(5):341-6.
161. Dalal KM, Woo Y, Kelly K, Galanis C, **Gönen M**, Fong Y, Coit DG. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. *Gastric Cancer*. 2008;11(4):206-13. Epub 2009 Jan 8.
162. Fahy BN, D'Angelica M, Dematteo RP, Blumgart LH, Weiser MR, Ostrovnaya I, **Gönen M**, Jarnagin WR. Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention. *Ann Surg Oncol*. 2008 Dec 3. [Epub ahead of print]
163. Vickers AJ, Cronin AM, Elkin EB, **Gönen M**. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. *BMC Med Inform Decis Mak*. 2008 Nov 26;8:53.
164. Moskowitz CS, Jia X, Schwartz LH, **Gönen M**. A simulation study to evaluate the impact of the number of lesions measured on response assessment. *Eur J Cancer*. 2009 Jan;45(2):300-10.
165. Noy A, Schöder H, **Gönen M**, Weissler M, Ertelt K, Cohler C, Portlock C, Hamlin P, Yeung HW. The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). *Ann Oncol*. 2009 Jan 12. [Epub ahead of print]
166. Bamboat ZM, Stableford JA, Plitas G, Burt BM, Nguyen HM, Welles AP, **Gönen M**, Young JW, DeMatteo RP. Human liver dendritic cells promote T cell hyporesponsiveness. *J Immunol*. 2009 Feb 15;182(4):1901-11.

167. O'Connor OA, Moskowitz C, Portlock C, Hamlin P, Straus D, Dumitrescu O, Sarasohn D, **Gönen M**, Butos J, Neylon E, Hamelers R, Mac-Gregor Cortelli B, Blumel S, Zelenetz AD, Gordon L, Wright JJ, Vose J, Cooper B, Winter J. Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial. *Br J Haematol*. 2009 Apr;145(1):34-9.
168. Katz SC, Shia J, Liau KH, **Gönen M**, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, Dematteo RP. Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma. *Ann Surg*. 2009 Mar 18. [Epub ahead of print]
169. Miksad RA, **Gönen M**, Lynch TJ, Roberts TG Jr. Interpreting Trial Results in Light of Conflicting Evidence: A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2009 27(13):2245-52
170. Strong VE, Devaud N, Allen PJ, **Gönen M**, Brennan MF, Coit D. Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study. *Ann Surg Oncol*. 2009 Jun;16(6):1507-13. Epub 2009 Apr 4.
171. Jhaver M, Coit D, Brennan M, Qin LX, **Gönen M**, Klimstra D, Tang L, Kelsen DP, Shah MA. Perineural Invasion After Preoperative Chemotherapy Predicts Poor Survival in Patients With Locally Advanced Gastric Cancer: Gene Expression Analysis With Pathologic Validation. *Am J Clin Oncol*. 2009 Apr 17. [Epub ahead of print]
172. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, **Gönen M**, Wong WD, Paty PB. Long-term survival after transanal excision of T1 rectal cancer. *Dis Colon Rectum*. 2009 Apr;52(4):577-82.
173. Carvajal RD, Tse A, Shah MA, Lefkowitz RA, **Gönen M**, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM. A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. *Pancreatol*. 2009 May 19;9(4):404-409. [Epub ahead of print]
174. **Gönen M**. Statistical aspects of gene signatures and molecular targets. *Gastrointest Cancer Res*. 2009 Mar;3(2 Suppl):S19-21.
175. Auer RC, Schulman AR, Tuorto S, **Gönen M**, Gonsalves J, Schwartz L, Ginsberg MS, Fong Y. Use of helical CT is associated with an increased incidence of postoperative pulmonary emboli in cancer patients with no change in the number of fatal pulmonary emboli. *J Am Coll Surg*. 2009 May;208(5):871-8; discussion 878-80.
176. Jarnagin WR, Schwartz LH, Gultekin DH, **Gönen M**, Haviland D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. *Ann Oncol*. 2009 Jun 2. [Epub ahead of print]

177. Carpizo DR, Are C, Jarnagin W, Dematteo R, Fong Y, **Gönen M**, Blumgart L, D'Angelica M. Liver Resection for Metastatic Colorectal Cancer in Patients with Concurrent Extrahepatic Disease: Results in 127 Patients Treated at a Single Center. *Ann Surg Oncol*. 2009 Jun 3. [Epub ahead of print]
178. Silberhumer GR, Zakian K, Malhotra S, Brader P, **Gönen M**, Koutcher J, Fong Y. Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts. *Br J Surg*. 2009 Jul;96(7):809-16.
179. **Gönen M**. Bayesian clinical trials: no more excuses (Editorial). *Clinical Trials*, 2009, 6:203-204.
180. Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, **Gönen M**, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, Dematteo RP. T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. *Ann Surg Oncol*. 2009 Jul 1. [Epub ahead of print]
181. Grewal RK, Larson SM, Pentlow CE, Pentlow KS, **Gönen M**, Qualey R, Natbony L, Tuttle RM. Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation. *J Nucl Med*. 2009 Sep 16. [Epub ahead of print]
182. Kelly KJ, Wong J, Gladdy R, Moore-Dalal K, Woo Y, **Gönen M**, Brennan M, Allen P, Fong Y, Coit D. Prognostic Impact of RT-PCR-Based Detection of Peritoneal Micrometastases in Patients with Pancreatic Cancer Undergoing Curative Resection. *Ann Surg Oncol*. 2009 Sep 18. [Epub ahead of print]
183. Selçuk Can A, Akal Yıldız E, Samur G, Rakıcioğlu N, Pekcan G, Ozbayrakçı S, Palaoğlu KE, **Gönen M**, Bersot TP. Optimal waist:height ratio cut-off point for cardiometabolic risk factors in Turkish adults. *Public Health Nutr*. 2009 Sep 28:1-8. [Epub ahead of print]
184. Gold JS, **Gönen M**, Gutiérrez A, Broto JM, García-Del-Muro X, Smyrk TC, Maki RG, Singer S, Brennan MF, Antonescu CR, Donohue JH, Dematteo RP. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. *Lancet Oncol*. 2009 Nov;10(11):1045-52.
185. Vickers AJ, Cronin AM, Kattan MW, **Gönen M**, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH; for The International Bladder Cancer Nomogram Consortium. Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach. *Cancer*. 2009 Oct 12;115(23):5460-5469
186. Goteti K, Edwin Garner C, Utley L, Dai J, Ashwell S, Moustakas DT, **Gönen M**, Schwartz GK, Kern SE, Zabudoff S, Brassil PJ. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. *Cancer Chemother Pharmacol*. 2009 Oct 16. [Epub ahead of print]
187. Sofocleous CT, Petre N, Manova-Todorova K, Petrovic L, **Gönen M**. Assessment of Viable Tumour Tissue Attached to Needle Applicators after Local Ablation of Liver Tumours. *Dig Surg*. 2009 Nov 13;26(5):434-435

188. Sima CS, Jarnagin WR, Fong Y, Elkin E, Fischer M, Wuest D, D'Angelica M, DeMatteo RP, Blumgart LH, **Gönen M**. Predicting the Risk of Peri-Operative Transfusion for Patients Undergoing Elective Hepatectomy. *Ann Surg*, 250:914-921.
189. Rathkopf D, Dickson MA, Feldman DR, Carvajal RD, Shah MA, Wu N, Lefkowitz R, **Gönen M**, Cane LM, Dials HJ, Winkelmann JL, Bosl GJ, Schwartz GK. Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. *Clin Cancer Res*. 2009 Dec 1;15(23):7405-11.
190. **Gönen M**, Schrag D, Weiser M. Nodal Staging Score: A Tool to Assess Adequate Staging of Node-Negative Colon Cancer. *J Clin Oncol* 2009 Nov 9. [Epub ahead of print]
191. **Gönen M**, Heller G. Lehmann Family of ROC Curves. *Medical Decision Making* (in press).